Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case

被引：4

作者：

Kaseda, Kaoru ^{[1
]}

Watanabe, Ken-ichi ^{[1
]}

Asakura, Keisuke ^{[1
]}

Kazama, Akio ^{[2
]}

机构：

[1] Sagamihara Kyodo Hosp, Dept Thorac Surg, Midori Ku, Sagamihara, Kanagawa 2525188, Japan

[2] Sagamihara Kyodo Hosp, Dept Pathol, Midori Ku, Sagamihara, Kanagawa 2525188, Japan

来源：

WORLD JOURNAL OF SURGICAL ONCOLOGY | 2015年 / 13卷

关键词：

Salvage surgery; Crizotinib; Anaplastic lymphoma kinase; Non-small cell lung cancer; ANAPLASTIC LYMPHOMA; CANCER; CHEMOTHERAPY; KINASE; GENE;

D O I：

10.1186/s12957-015-0480-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A 45-year-old female was diagnosed as having lung adenocarcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement, stage IV (T2bN3M1b). She was treated with crizotinib as second-line chemotherapy. The clinical stage after crizotinib treatment was ycT2aN0M0, stage IB. We performed a left lower lobectomy and lymph node dissection aimed at local control and pathological confirmation of the remaining tumor. The final pathological stage was ypT2aN2M0, stage IIIA with Ef 1b. To the best of our knowledge, this is the first case report of surgical resection in ALK rearrangement-positive lung adenocarcinoma after crizotinib treatment.

引用

页数：3

共 50 条

[1] Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case
Kaoru Kaseda
Ken-ichi Watanabe
Keisuke Asakura
Akio Kazama
World Journal of Surgical Oncology, 13
[2] ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report
Qiu, Ye
Li, Bixun
Zhang, Yihong
Guo, Xiaoyun
Xiang, Chunzhi
Wang, Congshui
Lu, Yang
Ren, Shuang
Zhao, Juan
MEDICINE, 2019, 98 (11)
[3] LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
Yang, Yanlong
Zheng, Hongbo
Li, Zizhe
Shi, Shuchen
Zhong, Lang
Gong, Longlong
Lan, Bin
FRONTIERS IN ONCOLOGY, 2022, 12
[4] Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: A case report
Kosaka, Takayuki
Yajima, Toshiki
Yamaki, Ei
Nakazawa, Seshiru
Tomizawa, Kenji
Onozato, Ryoichi
Yamazaki, Ayako
Hirato, Junko
Yatabe, Yasushi
Shimizu, Kimihiro
Mogi, Akira
Shirabe, Ken
MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (03) : 309 - 312
[5] Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement-positive lung adenocarcinoma: A case report
Takakuwa, Osamu
Oguri, Tetsuya
Yokoyama, Midori
Hijikata, Hisatoshi
Uemura, Takehiro
Ohkubo, Hirotsugu
Maeno, Ken
Niimi, Akio
MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 121 - 123
[6] Successful treatment with crizotinib after alectinib-induced interstitial lung disease
Zhu, Ning
Lin, Shanhong
He, Lei
Wang, Linfeng
Kong, Weiliang
Cao, Chao
SAGE OPEN MEDICAL CASE REPORTS, 2021, 9
[7] Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
Ryu, Woo Kyung
Cha, Hyungkeun
Park, Mi Hwa
Kim, Jung Soo
Choi, Jeong-Seok
Kim, Lucia
Lee, Kyung-Hee
Nam, Hae-Seong
FRONTIERS IN ONCOLOGY, 2022, 12
[8] Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report
Campos-Gomez, Saul
Lara-Guerra, Humberto
Routbort, Mark J.
Lu, Xinyan
Simon, George R.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (02) : E254 - E257
[9] Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment
Shen, Hong
Zhong, Xian
Ge, Xiao-qin
Huang, Jian-Jin
Yuan, Ying
CLINICAL RESPIRATORY JOURNAL, 2010, 4 (03) : 192 - 193
[10] Crizotinib in the treatment of non-small-cell lung carcinoma
Pluzanski, Adam
Piorek, Aleksandra
Krzakowski, Maciej
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (06): : 480 - 484

← 1 2 3 4 5 →